Displaying 1 - 6 of 6
| Active Ingredient | EMPAGLIFLOZIN|METFORMIN |
| Therapeutic Class | SODIUM GLUCOSE CO TRANSPORTER INHIBITOR |
| Indications | Indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate |
| Caution | Lactic acidosis is a metabolic complication that can occur due to metformin accumulation during treatment and is fatal in ~50% of cases. Necrotizing fasciitis of the perineum (Fournier gangrene) repor More ... |
| Dose Range |
Take twice daily with meals (ie, divide total daily dose into 2 doses/day) For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin. |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | GLIBENCLAMIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications |
Diabetes Mellitus. More potent than chlorpropamide but shorter acting and not affected by renal failure. Half-life: 10 hours; Duration of Action: 24 hours. Glyburide is the micronised form More ... |
| Caution | Hypoglycemia: Occurs more commonly in elderly patients, even with low doses. It is best avoided in the elderly . c.f. prescribing in liver and renal disease p. 14; 30. |
| Dose Range |
2.5-5mg to a maximum of 20mg daily . Take with breakfast. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLICLAZIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications | Treatment of diabetes mellitus. May be of benefit in retinopathy. |
| Caution | Gastro intestinal upset, nausea, hypoglycemia, weight gain, dizziness. c.f. prescribing in liver and renal disease p. 14; 30. |
| Dose Range |
Intial dose: 40- 80 mg daily with breakfast, gradually increasing to 320 mg daily . Doses of more than 160 mg daily are given in 2 divided doses. M odified-release: initial dose is 30 mg once daily , increasing if necessary in step s of |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLIMEPIRIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLYBURIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PIOGLITAZONE |
| Therapeutic Class | THIAZOLIDINEDIONES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |